RecruitingPhase 4NCT06812832

Simethicone as Part of ERAS in Bariatric Surgery Patients

Simethicone as Part of an Enhanced Recovery After Surgery (ERAS) Protocol


Sponsor

Madigan Army Medical Center

Enrollment

260 participants

Start Date

Apr 8, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

By conducting this study, we hope to assess if simethicone (also known as Gas Relief or GasX) has an effect on improving gas pain and bloating specifically in patients undergoing foregut procedures to include bariatric procedures (sleeve gastrectomy, Roux-en-Y gastric bypass), hiatal hernia, and gastric surgery. The purpose of this research is to gather information on the safety and effectiveness of simethicone. Simethicone (more commonly known as Gas Relief or Gas-X) relieves pressure, bloating, and fullness commonly referred to as gas. It is FDA approved. The use of this medication in this research study is consistent with labeling indications.


Eligibility

Min Age: 18 YearsMax Age: 89 Years

Inclusion Criteria1

  • Foregut procedures

Exclusion Criteria4

  • Non-foregut procedures
  • Allergy to simethicone
  • Pregnancy or breastfeeding
  • Minors under 18 years of age

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSimethicone 80 MG

Patients will receive simethicone 80mg four times per day for 2 weeks post-operatively.

DRUGPlacebo

Patients in the control group will receive a placebo pill four times per day for 2 weeks


Locations(1)

Madigan Army Medical Center

Tacoma, Washington, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06812832


Related Trials